Heidelberg Pharma Investor Relations Material
Latest events
Status Update
Heidelberg Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Heidelberg Pharma AG
Access all reports
Heidelberg Pharma is a biopharmaceutical company that focuses on oncology and antibody targeted amanitin conjugates (ATAC). Their innovations are based on cell immunotherapy and the drug amanitin conjugates (ATAC). The tumor cells are attacked by immune cells, which recognize the amanitin antigen as a foreign body. This way the treatment causes no mutilation of healthy tissue.
Key slides for Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
HPHA
Country
🇩🇪 Germany